Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARAV NASDAQ:FPRX NASDAQ:MNPR NASDAQ:NATR NASDAQ:OVID On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAVAravive$0.04$0.04$0.04▼$2.46N/AN/AN/AN/AFPRXFive Prime Therapeutics$38.00$37.94$2.61▼$38.90$1.77B4.41.98 million shsN/AMNPRMonopar Therapeutics$59.53+4.4%$40.04$3.90▼$59.53$367.12M1.239,738 shs14,078 shsNATRNature's Sunshine Products$16.99+0.9%$16.02$11.01▼$18.06$299.70M1.1166,952 shs16,501 shsOVIDOvid Therapeutics$1.21+6.1%$0.83$0.24▼$1.47$86.04M0.351.03 million shs266,923 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAVAravive0.00%0.00%0.00%0.00%0.00%FPRXFive Prime Therapeutics0.00%0.00%0.00%0.00%0.00%MNPRMonopar Therapeutics+4.61%+26.86%+59.62%+72.73%+1,260.38%NATRNature's Sunshine Products-1.00%-1.52%+1.81%+14.95%+21.94%OVIDOvid Therapeutics-10.94%-8.06%+17.53%+285.27%-2.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAVAravive$0.04$0.04$0.04▼$2.46N/AN/AN/AN/AFPRXFive Prime Therapeutics$38.00$37.94$2.61▼$38.90$1.77B4.41.98 million shsN/AMNPRMonopar Therapeutics$59.53+4.4%$40.04$3.90▼$59.53$367.12M1.239,738 shs14,078 shsNATRNature's Sunshine Products$16.99+0.9%$16.02$11.01▼$18.06$299.70M1.1166,952 shs16,501 shsOVIDOvid Therapeutics$1.21+6.1%$0.83$0.24▼$1.47$86.04M0.351.03 million shs266,923 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAVAravive0.00%0.00%0.00%0.00%0.00%FPRXFive Prime Therapeutics0.00%0.00%0.00%0.00%0.00%MNPRMonopar Therapeutics+4.61%+26.86%+59.62%+72.73%+1,260.38%NATRNature's Sunshine Products-1.00%-1.52%+1.81%+14.95%+21.94%OVIDOvid Therapeutics-10.94%-8.06%+17.53%+285.27%-2.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARAVAravive 0.00N/AN/AN/AFPRXFive Prime Therapeutics 0.00N/AN/AN/AMNPRMonopar Therapeutics 3.00Buy$71.7526.26% UpsideNATRNature's Sunshine Products 3.00Buy$20.5020.73% UpsideOVIDOvid Therapeutics 3.17Buy$3.10160.07% UpsideCurrent Analyst Ratings BreakdownLatest FPRX, ARAV, MNPR, NATR, and OVID Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/16/2025MNPRMonopar TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.009/15/2025MNPRMonopar TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$87.009/9/2025MNPRMonopar TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$87.009/3/2025MNPRMonopar TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$77.009/2/2025MNPRMonopar TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$80.008/27/2025MNPRMonopar TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$74.008/26/2025MNPRMonopar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$70.008/13/2025MNPRMonopar TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.008/8/2025OVIDOvid TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.008/1/2025NATRNature's Sunshine ProductsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$21.00 ➝ $22.007/7/2025MNPRMonopar TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$74.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARAVAravive$9.14MN/AN/AN/AN/AN/AFPRXFive Prime Therapeutics$14.87M119.01N/AN/A$4.13 per share9.20MNPRMonopar TherapeuticsN/AN/AN/AN/A$9.02 per shareN/ANATRNature's Sunshine Products$454.36M0.66$1.25 per share13.62$8.71 per share1.95OVIDOvid Therapeutics$570K148.71N/AN/A$0.96 per share1.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARAVAravive-$76.32MN/A0.00∞N/AN/AN/AN/AN/AFPRXFive Prime Therapeutics-$137.20M-$3.92N/AN/AN/A-554.71%-75.84%-49.08%N/AMNPRMonopar Therapeutics-$15.59M-$3.33N/AN/AN/AN/A-41.76%-39.49%11/14/2025 (Estimated)NATRNature's Sunshine Products$7.70M$0.7422.94∞N/A3.06%10.19%6.71%11/6/2025 (Estimated)OVIDOvid Therapeutics-$26.43M-$0.53N/AN/AN/A-574.44%-58.87%-43.18%11/11/2025 (Estimated)Latest FPRX, ARAV, MNPR, NATR, and OVID EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025OVIDOvid Therapeutics-$0.16-$0.06+$0.10-$0.06$0.09 million$6.27 million8/12/2025Q2 2025MNPRMonopar Therapeutics-$0.47-$0.35+$0.12-$0.35N/AN/A7/31/2025Q2 2025NATRNature's Sunshine Products$0.1650$0.35+$0.1850$0.28$113.10 million$114.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARAVAraviveN/AN/AN/AN/AN/AFPRXFive Prime TherapeuticsN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ANATRNature's Sunshine ProductsN/AN/AN/AN/AN/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARAVAraviveN/AN/AN/AFPRXFive Prime TherapeuticsN/A5.355.35MNPRMonopar TherapeuticsN/A33.9333.93NATRNature's Sunshine ProductsN/A2.271.35OVIDOvid Therapeutics0.234.724.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARAVAravive35.80%FPRXFive Prime Therapeutics67.28%MNPRMonopar Therapeutics1.83%NATRNature's Sunshine Products79.40%OVIDOvid Therapeutics72.24%Insider OwnershipCompanyInsider OwnershipARAVAravive60.40%FPRXFive Prime Therapeutics6.40%MNPRMonopar Therapeutics20.50%NATRNature's Sunshine Products5.60%OVIDOvid Therapeutics13.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARAVAravive20N/AN/ANo DataFPRXFive Prime Therapeutics8746.57 millionN/AOptionableMNPRMonopar Therapeutics106.17 million4.91 millionNot OptionableNATRNature's Sunshine Products85017.64 million16.65 millionOptionableOVIDOvid Therapeutics6071.11 million61.80 millionOptionableFPRX, ARAV, MNPR, NATR, and OVID HeadlinesRecent News About These CompaniesOvid Therapeutics Regains Nasdaq ComplianceSeptember 16 at 2:39 PM | msn.comOvid Therapeutics (NASDAQ:OVID) Receives $3.10 Average Price Target from AnalystsSeptember 10, 2025 | americanbankingnews.comOvid Therapeutics (NASDAQ:OVID) Receives Average Recommendation of "Buy" from BrokeragesSeptember 8, 2025 | marketbeat.comHC Wainwright Cuts Earnings Estimates for Ovid TherapeuticsAugust 29, 2025 | marketbeat.comAffinity Asset Advisors LLC Invests $208,000 in Ovid Therapeutics $OVIDAugust 28, 2025 | marketbeat.comLucid Capital Initiates Ovid Therapeutics Inc. (OVID) at Buy with $5.50 TargetAugust 24, 2025 | finance.yahoo.comLucid Capital Initiates Ovid Therapeutics Inc. (OVID) at Buy with $5.50 TargetAugust 23, 2025 | insidermonkey.comOvid Therapeutics (NASDAQ:OVID) Short Interest Up 54.8% in JulyAugust 22, 2025 | marketbeat.comSpotlight On 3 Promising Penny Stocks With Over $60M Market CapAugust 20, 2025 | uk.finance.yahoo.comWilliam Blair Predicts Higher Earnings for Ovid TherapeuticsAugust 19, 2025 | marketbeat.comQ3 EPS Estimates for Ovid Therapeutics Increased by B. RileyAugust 19, 2025 | marketbeat.comWedbush Research Analysts Lower Earnings Estimates for OVIDAugust 19, 2025 | marketbeat.comOvid Therapeutics (NASDAQ:OVID) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPSAugust 17, 2025 | marketbeat.comOvid Therapeutics (NASDAQ:OVID) Rating Increased to Hold at Wall Street ZenAugust 17, 2025 | marketbeat.comOvid Therapeutics Second Quarter 2025 Earnings: Beats ExpectationsAugust 16, 2025 | finance.yahoo.comOvid Therapeutics Reports Increased Revenue Amid ChallengesAugust 14, 2025 | msn.comOvid Therapeutics Navigates FDA Disruptions and Government ChallengesAugust 14, 2025 | tipranks.comOvid Therapeutics: Strategic Advances and Promising Developments Justify Buy RatingAugust 13, 2025 | tipranks.comOvid Therapeutics initiated with a Buy at Lucid CapitalAugust 13, 2025 | msn.comOvid Therapeutics Transfers Stock to Nasdaq Capital MarketAugust 13, 2025 | msn.comOvid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue EstimatesAugust 13, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFPRX, ARAV, MNPR, NATR, and OVID Company DescriptionsAravive NASDAQ:ARAV$0.04 0.00 (0.00%) As of 09/16/2025Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.Five Prime Therapeutics NASDAQ:FPRXFive Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.Monopar Therapeutics NASDAQ:MNPR$59.53 +2.53 (+4.44%) As of 11:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Nature's Sunshine Products NASDAQ:NATR$16.99 +0.15 (+0.89%) As of 11:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.Ovid Therapeutics NASDAQ:OVID$1.21 +0.07 (+6.14%) As of 11:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case This Defense Stock Is Up 113% This Year—Is It Still a Buy? Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
